WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
about
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis RestrictionNiclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.Characterization of Lgr5+ Progenitor Cell Transcriptomes after Neomycin Injury in the Neonatal Mouse CochleaLost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma.WNT7A Regulation by miR-15b in Ovarian Cancer.Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326.Niclosamide: Beyond an antihelminthic drug.Niclosamide As a Potential Nonsteroidal Therapy for Endometriosis That Preserves Reproductive Function in an Experimental Mouse Model.FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation.An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.FGF1 induces resistance to chemotherapy in ovarian granulosa tumor cells through regulation of p53 mitochondrial localization.Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.Niclosamide sensitizes nasopharyngeal carcinoma to radiation by downregulating Ku70/80 expression.JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis.High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma
P2860
Q26743403-DFC8626D-B576-4C78-83D9-EEB49836CF74Q30275354-C9604235-35F6-417B-A197-8CB312BB7DF7Q33869949-AE530CC5-82F3-4A96-8B5B-B3E014BAA5BFQ35229044-3AB1981F-D8C4-4799-ABEA-82A874E55A64Q36022349-562467BF-25E2-4568-B477-5BC9F1E95493Q37100097-C5BA130E-5BBF-4D5B-A7E9-79064BDB3DCFQ38736415-36C4AF13-B1E2-4E55-9BEC-AB9C229F28FFQ38852126-82B3101E-DF5C-44B8-8D21-A2A2602992D7Q39227540-BDD053F7-C894-4092-83A9-BA87319800F5Q41634189-13F826CE-F757-4CD8-85E8-A6D44BDA502CQ42358220-3FDF96F9-78AD-4830-ADDF-9426751FDE3CQ51173657-03F3ED2F-5344-40DB-B97A-F1A55DAF6988Q52691547-E7F0B876-4C44-430D-BB28-F897DFCF2521Q52807468-14B078BE-EB7A-44C1-9770-BC910EC1CA5CQ55244874-1DFD6E41-CADE-4832-9D4D-AD727F3FD062Q55269538-ACA5C796-23BB-4668-B12C-DC65CF5C8581Q55418713-5E003008-D5A9-4FC7-B37F-670B08B323A3Q58563343-2CD88F05-9FB1-42D6-A636-27ABE10CBCA9
P2860
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@ast
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@en
type
label
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@ast
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@en
prefLabel
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@ast
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
WNT7A/β-catenin signaling indu ...... niclosamide in ovarian cancer
@en
P2093
G R Stodden
J A MacLean Ii
M E Lindberg
P2860
P2888
P304
P356
10.1038/ONC.2014.277
P407
P577
2014-09-01T00:00:00Z